Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?
Monoclonal antibodies have many potential therapeutic benefits. However, when applied to humans, mouse monoclonal antibodies have several disadvantages. Here Carl Borrebaeck and colleagues describe a strategy to overcome the anti-Gal activity, thought to be one of the reasons why mouse mAbs have a limited half-life.
Borrebaeck
C K
CK
Dept of Immunotechnology, Lund University, Sweden.
Malmborg
A C
AC
Ohlin
M
M
D000818:Animals; D000910:Antibodies, Heterophile / Q000097:blood; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D002240:Carbohydrate Sequence; D004187:Disaccharides / Q000737:chemistry / Q000276:immunology; D006031:Glycosylation; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D000910:Antibodies, Heterophile; D000911:Antibodies, Monoclonal; D004187:Disaccharides; C055075:galactosyl-(1-3)galactose